TCG Crossover Management LLC Takes Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

TCG Crossover Management LLC purchased a new stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,501,624 shares of the company's stock, valued at approximately $32,735,000. Dianthus Therapeutics accounts for approximately 3.2% of TCG Crossover Management LLC's portfolio, making the stock its 11th biggest position. TCG Crossover Management LLC owned approximately 5.07% of Dianthus Therapeutics at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the stock. R Squared Ltd acquired a new stake in Dianthus Therapeutics in the 4th quarter valued at $26,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Dianthus Therapeutics during the fourth quarter worth about $33,000. KBC Group NV acquired a new position in shares of Dianthus Therapeutics during the 4th quarter worth about $35,000. AlphaQuest LLC lifted its stake in Dianthus Therapeutics by 273.1% in the 4th quarter. AlphaQuest LLC now owns 4,197 shares of the company's stock valued at $91,000 after buying an additional 3,072 shares in the last quarter. Finally, Intech Investment Management LLC acquired a new stake in Dianthus Therapeutics in the 4th quarter worth about $201,000. Hedge funds and other institutional investors own 47.53% of the company's stock.

Dianthus Therapeutics Price Performance

Shares of NASDAQ DNTH remained flat at $21.70 during trading on Friday. The stock had a trading volume of 150,873 shares, compared to its average volume of 264,548. The company's 50-day moving average is $19.85 and its two-hundred day moving average is $22.68. The stock has a market cap of $697.13 million, a price-to-earnings ratio of -8.68 and a beta of 1.48. Dianthus Therapeutics, Inc. has a fifty-two week low of $13.37 and a fifty-two week high of $32.27.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its earnings results on Tuesday, March 11th. The company reported ($0.81) EPS for the quarter, topping analysts' consensus estimates of ($0.85) by $0.04. The company had revenue of $1.33 million for the quarter, compared to the consensus estimate of $1.40 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. On average, analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on DNTH shares. Wedbush reissued an "outperform" rating and set a $36.00 target price on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Guggenheim reissued a "buy" rating and issued a $84.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Dianthus Therapeutics has an average rating of "Buy" and a consensus target price of $54.33.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.